Literature DB >> 8906024

Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma.

J E Kingston1, J L Hungerford, S A Madreperla, P N Plowman.   

Abstract

OBJECTIVE: To determine the visual anatomical results and survival after combined chemotherapy and whole eye radiotherapy for patients with bilateral Reese-Ellsworth group V retinoblastoma.
SETTING: A national referral center for retinoblastoma. PATIENTS: Fourteen patients with bilateral Reese-Ellsworth group V retinoblastoma seen between March 1, 1989, and April 30, 1995, were treated.
INTERVENTIONS: Patients were treated with chemotherapy (using carboplatin, etoposide, and vincristine) and whole eye radiotherapy (40-44 Gy in 20-22 equivalent fractions). A medical record review was performed to determine outcomes. MAIN OUTCOME MEASURES: Survival, eye preservation rate, and visual acuity.
RESULTS: Two patients died, 1 from a primitive neuroectodermal tumor and the other from the meningeal spread of retinoblastoma. Four eyes were enucleated primarily because of severe disease at presentation. Of the remaining 20 eyes, 6 required enucleation. The disease recurred in 4 of those patients, and neovascular glaucoma developed in 2 patients. Of the 12 surviving children, 5 have a visual acuity better than l/60 in at least 1 eye.
CONCLUSION: Although most of the treated group V eyes could be salvaged with chemotherapy plus radiotherapy, the resultant visual acuity was often poor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8906024     DOI: 10.1001/archopht.1996.01100140539004

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  47 in total

Review 1.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Comparison of high-risk histopathological features in eyes with primary or secondary enucleation for retinoblastoma.

Authors:  Rachel C Brennan; Ibrahim Qaddoumi; Catherine A Billups; Tammy L Free; Barrett G Haik; Carlos Rodriguez-Galindo; Matthew W Wilson
Journal:  Br J Ophthalmol       Date:  2015-04-14       Impact factor: 4.638

Review 3.  Neovascular glaucoma.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2007-08-08       Impact factor: 21.198

4.  Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age.

Authors:  Dan S Gombos; Alison Kelly; Pietro G Coen; Judith E Kingston; John L Hungerford
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

5.  Systemic carboplatin for retinoblastoma: change in tumour size over time.

Authors:  D H Abramson; S D Lawrence; K L Beaverson; T C Lee; I S Rollins; I J Dunkel
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

Review 6.  Retinoblastoma.

Authors:  Raksha Rao; Santosh G Honavar
Journal:  Indian J Pediatr       Date:  2017-06-16       Impact factor: 1.967

Review 7.  Management of retinoblastoma in children: current status.

Authors:  Guillermo Chantada; Paula Schaiquevich
Journal:  Paediatr Drugs       Date:  2015-06       Impact factor: 3.022

Review 8.  Current treatment and management of retinoblastoma.

Authors:  Dan S Gombos; And Patricia Chevez-Barrios
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

9.  Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors.

Authors:  Carol L Shields; Arman Mashayekhi; Jacqueline Cater; Abdallah Shelil; Anna T Meadows; Jerry A Shields
Journal:  Trans Am Ophthalmol Soc       Date:  2004

Review 10.  Current management strategies for intraocular retinoblastoma.

Authors:  Jonathan W Kim; David H Abramson; Ira J Dunkel
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.